Home PD, Mehta R, Hafidh KAS, et al. - This study’s findings demonstrate that iGlarLixi seems to offer clinical benefits in glucose control and body weight change in people needing both basal and meal-time intervention.

• Researchers conducted a systematic literature search of randomized controlled trials (RCTs) including eight RCTs (duration 26–30 weeks).

• The results showed that the mean variation in HbA1c change with iGlarLixi exceeded that for IDegAsp: -0.64 (95% credible interval -1.01, -0.28) %-units (-7.0 [-11.0, -3.1] mmol/mol) for all trials, -0.39 (-0.55, -0.23) %-units (-4.3 [-6.0, -2.5] mmol/mol) for international, and -0.88 (-1.11, -0.64) %-units (-9.6 [-12.1, -7.0] mmol/mol) for Japanese trials.

• They found greater HbA1c target achievement (<7.0 %-units [<53 mmol/mol]) for iGlarLixi in all trials (odds ratio 2.50 [1.06, 5.56]) and Japanese trials (2.17 [1.27, 3.70]) but not in international trials (2.17 [0.42, 11.11]).

• According to the findings, analyses implying differences in mean post-meal SMPG were significantly lower by 1.0–2.0 mmol/L (18–36 mg/dL) with iGlarLixi in all analyses.

• It has been reported that body weight change was more favorable (1–2 kg) for iGlarLixi vs IDegAsp for all analyses (p<0.05).

• As per the findings, comparisons of hypoglycemia were inconclusive owing to differences in definitions between studies.

• Because of gastrointestinal intolerance, adverse events were more frequent with iGlarLixi.